[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-378977-105":59,"doc-detail-378977-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","fapi-petct-imagingan-updated-review","FAPI PET/CT Imaging—An Updated Review","","Positron Emission Tomography (PET) using [18F]FDG as the standard workhorse is constrained by limited tumor subtype specificity and low sensitivity. Fibroblast activation protein (FAP), a type II transmembrane glycoprotein expressed on cancer-associated fibroblasts within tumor stroma, enables a pan-cancer target with selective overexpression across many neoplasms. Radiolabeled FAP inhibitors (FAPI) have been developed for molecular imaging and potential theranostic use. Existing FAPI PET/CT evidence supports ongoing multidisciplinary clinical research, and this review synthesizes diagnostic applications, compares with FDG, addresses pitfalls, and outlines future directions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fapi-petct-imagingan-updated-review/378977/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fapi-petct-imagingan-updated-review/378977.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is [18F]FDG PET/CT limited in oncology?","Question",{"text":113,"@type":114},"FDG uptake mainly reflects glucose transport and metabolism rather than malignancy-specific biology, resulting in limited specificity and low sensitivity for certain tumor subtypes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is the clinical rationale for FAPI PET/CT?",{"text":118,"@type":114},"FAP is expressed on cancer-associated fibroblasts that form a major component of the tumor microenvironment, with selective overexpression across many cancers. Radiolabeled FAPI tracers are therefore investigated as targeted PET agents and potential theranostic tools.",{"name":120,"@type":111,"acceptedAnswer":121},"What does the review focus on regarding FAPI PET/CT?",{"text":122,"@type":114},"It summarizes existing literature emphasizing diagnostic applications, compares imaging performance with FDG, highlights pitfalls, and discusses future directions for the field.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},378977,1790521603,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","diagnostics  \nReview  \nFAPI PET/CT Imaging—An Updated Review  \nKunal Ramesh Chandekar 1, Arun Prashanth 2, Sobhan Vinjamuri 3 and Rakesh Kumar 1, *  \nCitation: Chandekar, K.R.; Prashanth, A.; Vinjamuri, S.; Kumar, R. FAPIPET/CT Imaging—An Updated Review. Diagnostics 2023, 13, 2018 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)diagnostics13122018  \nAcademic Editor: Andor W.J.M. Glaudemans  \nReceived: 25 April 2023  \nRevised: 25 May 2023  \nAccepted: 26 May 2023  \nPublished: 9 June 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India; [kunal.chandekar@aiims.edu](kunal.chandekar@aiims.edu)  \n2 Department of Nuclear Medicine, MIOT International Hospital, Chennai 600089, India; [dr.arunprashanth@gmail.com](dr.arunprashanth@gmail.com)  \n3 Department of Nuclear Medicine, Royal Liverpool and Broadgreen University Hospital, Liverpool L7-8YE, UK; [sobhan.vinjamuri@gmail.com](sobhan.vinjamuri@gmail.com)  \n* Correspondence: [rkphulia@yahoo.com](rkphulia@yahoo.com); Tel.: +91-011-26544472  \nAbstract: Despite revolutionizing the field of oncological imaging, Positron Emission Tomography (PET) with [18F]Fluorodeoxyglucose (FDG) as its workhorse is limited by a lack of specificity and low sensitivity in certain tumor subtypes. Fibroblast activation protein (FAP), a type II transmembrane glycoprotein, is expressed by cancer-associated fibroblasts (CAFs) that form a major component of the tumor stroma. FAP holds the promise to be a pan-cancer target, owing to its selective over-expression in a vast majority of neoplasms, particularly epithelial cancers. Several radiolabeled FAP inhibitors (FAPI) have been developed for molecular imaging and potential theranostic applications. Preliminary data on FAPI PET/CT remains encouraging, with extensive multi-disciplinary clinical research currently underway. This review summarizes the existing literature on FAPI PET/CT imaging with an emphasis on diagnostic applications, comparison with FDG, pitfalls, and future directions.  \nKeywords: fibroblast activation protein (FAP); FAPI; PET/CT; imaging; diagnostic; theranostics  \n1. Introduction  \nThe field of oncology has been revolutionized by molecular imaging which assesses tumor biology as opposed to conventional radiologic imaging which focuses on morphological anatomy [1] . Molecular imaging permits non-invasive visualization of physiological or pathological processes at the cellular or sub-cellular level. Positron emission tomography/computed tomography (PET/CT) is a hybrid imaging tool that provides complementary functional and structural information [2] . [18F]Fluorodeoxyglucose (FDG),first developed in the late 1970s as a tracer to map regional cerebral metabolism, is now the most universally used PET tracer having a myriad of oncological and non-oncological applications [3,4] . Despite its undeniable clinical utility, FDG uptake is a surrogate for glucose transport/metabolism and is not specific for malignancy. Subsequent translational research led to the development of more specific tracers such as radiolabeled somatostatin receptor (SSTR) targeting agents and prostate-specific membrane antigen (PSMA) ligands, which have successfully been incorporated into modern-day management practices of neuroendocrine tumors and prostate cancer, respectively [5] . The ever-evolving search for cellular targets led to the discovery of fibroblast activation protein (FAP), a transmembrane glycoprotein expressed on activated fibroblasts such as cancer-associated fibroblasts (CAFs) [6] . Preliminary evidence has generated raging scientific i","cbCaibVydEmXr88v","https://ap.wps.com/l/cbCaibVydEmXr88v","pdf",3515379,22,"English","# Abstract\n# Introduction\n# Understanding Tumor Biology","[{\"question\":\"Why is [18F]FDG PET/CT limited in oncology?\",\"answer\":\"FDG uptake mainly reflects glucose transport and metabolism rather than malignancy-specific biology, resulting in limited specificity and low sensitivity for certain tumor subtypes.\"},{\"question\":\"What is the clinical rationale for FAPI PET/CT?\",\"answer\":\"FAP is expressed on cancer-associated fibroblasts that form a major component of the tumor microenvironment, with selective overexpression across many cancers. Radiolabeled FAPI tracers are therefore investigated as targeted PET agents and potential theranostic tools.\"},{\"question\":\"What does the review focus on regarding FAPI PET/CT?\",\"answer\":\"It summarizes existing literature emphasizing diagnostic applications, compares imaging performance with FDG, highlights pitfalls, and discusses future directions for the field.\"}]","FAPI PET/CT Imaging—An Updated Review | PDF",1790233498,55]